Compare YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF (QDTY) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF vs Tango Therapeutics Inc. — how do they compare? YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF trades at $37.9 (market cap $29.26M), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: Tango Therapeutics Inc. is far larger — about 128.2× YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF's market cap, and Tango Therapeutics Inc. is trading nearer its 52-week high, YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF for 64 Days and Tango Therapeutics Inc. for 0 Days on average.
| QDTY | TNGX | |
|---|---|---|
Market Cap | $29.26M | $3.75B |
Volume | 13,576 | 9,619,106 |
Sector | Income / Options Overlay | Health |
52-Week High | $46.71 | $32.90 |
52-Week Low | $36.57 | $7.50 |
Typical Hold Time | 64 Days | 0 Days |
Enterprise Value | — | $2.77B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
QDTY trades at $38.94, down 0.36% with bearish technical signals from moving averages. The ETF maintains a consistent weekly dividend distribution strategy, with recent payments ranging from $0.19 to $0.30 per share. Technical indicators show mixed signals with RSI in neutral territory while ADX suggests weakening trend strength. The stock faces resistance at $40 with support clustered around $39.
The outlook remains cautious given bearish technical momentum and concentrated support levels. Dividend consistency provides income appeal, but technical weakness and tight trading range near current levels suggest limited near-term upside potential. Key risks include market volatility impact on covered call strategies and dependency on Nasdaq 100 performance.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF
QDTY is an actively managed ETF that employs a synthetic covered call strategy on the Nasdaq-100 Index using zero-days-to-expiration (0DTE) options. It aims to generate high weekly income by selling daily call options, providing limited participation in the index's upside while remaining fully exposed to its downside risk.
Read more on QDTY →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
